Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients

N. Greppi, L. Mazzucco, G. Galetti, F. Bona, E. Petrillo, C. Smacchia, E. Raspollini, P. Cossovich, R. Caprioli, P. Borzini, P. Rebulla, M. Marconi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

We evaluated growth factor contents and clinical efficacy of allogeneic platelet gel (PG) prepared with standard blood banking procedures from routine platelet concentrates (PCs) obtained from buffy coats. The PGs were used to treat 11 hypomobile very elderly patients unable to undergo autologous blood processing and previously ineffectively treated with expensive advanced medications for 8-275 weeks.PGs were prepared by platelet activation with human thrombin or commercial batroxobin. Median and range growth factor contents (ng/mL) were: platelet derived growth factor (PDGF-AB/-BB) 112 (31-157) and 20 (3.8-34); transforming growth factor (TGF-β1/-β2) 214 (48-289) and 0.087 (0.03-0.28); basic-fibroblast growth factor (b-FGF) 0.03 (0.006-0.214); vascular endothelial growth factor (VEGF) 1.15 (0.18-2.46); epidermal growth factor (EGF) 4.50 (0.87-6.64); insulin-like growth factor (IGF-l) 116 (72-156).In the clinical study, 222 PGs were used within 2 h of activation to treat 14 chronic skin ulcers in the 11 patients. No improvement was seen in 3 patients with 24, 27 and 30 cm3 ulcers who could be treated for no more than 4, 7 and 8 weeks due to progressively worsening clinical conditions, while 11 ulcers with 3.2 cm3 median size (range 0.2-3.6) in the remaining 8 patients showed 91 ± 14 % reduction after a median of 12 weeks (range 1-20). Cost of PG treatment (19,976 euro) amounted to about 10% of the ineffective advanced medication hospital reimbursement fees (191,236 euro).This study supports efficacy and feasibility of allogeneic PG to treat recalcitrant ulcers in very elderly hypomobile patients for whom autologous blood processing may be difficult.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalBiologicals
Volume39
Issue number2
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Platelets
Ulcer
Blood Platelets
Gels
Blood
Intercellular Signaling Peptides and Proteins
Batroxobin
Chemical activation
Skin Ulcer
Therapeutics
Blood Banks
Fees and Charges
Platelet-Derived Growth Factor
Platelet Activation
Transforming Growth Factors
Somatomedins
Fibroblast Growth Factor 2
Processing
Epidermal Growth Factor
Thrombin

Keywords

  • Allogeneic platelet gel
  • Buffy coat
  • Platelet concentrate
  • Platelet growth factors
  • Skin ulcers

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering
  • Immunology and Microbiology(all)
  • Pharmacology

Cite this

Greppi, N., Mazzucco, L., Galetti, G., Bona, F., Petrillo, E., Smacchia, C., ... Marconi, M. (2011). Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients. Biologicals, 39(2), 73-80. https://doi.org/10.1016/j.biologicals.2011.01.002

Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients. / Greppi, N.; Mazzucco, L.; Galetti, G.; Bona, F.; Petrillo, E.; Smacchia, C.; Raspollini, E.; Cossovich, P.; Caprioli, R.; Borzini, P.; Rebulla, P.; Marconi, M.

In: Biologicals, Vol. 39, No. 2, 03.2011, p. 73-80.

Research output: Contribution to journalArticle

Greppi, N, Mazzucco, L, Galetti, G, Bona, F, Petrillo, E, Smacchia, C, Raspollini, E, Cossovich, P, Caprioli, R, Borzini, P, Rebulla, P & Marconi, M 2011, 'Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients', Biologicals, vol. 39, no. 2, pp. 73-80. https://doi.org/10.1016/j.biologicals.2011.01.002
Greppi, N. ; Mazzucco, L. ; Galetti, G. ; Bona, F. ; Petrillo, E. ; Smacchia, C. ; Raspollini, E. ; Cossovich, P. ; Caprioli, R. ; Borzini, P. ; Rebulla, P. ; Marconi, M. / Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients. In: Biologicals. 2011 ; Vol. 39, No. 2. pp. 73-80.
@article{540748703bf248b2bf2e42d94d8d190e,
title = "Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients",
abstract = "We evaluated growth factor contents and clinical efficacy of allogeneic platelet gel (PG) prepared with standard blood banking procedures from routine platelet concentrates (PCs) obtained from buffy coats. The PGs were used to treat 11 hypomobile very elderly patients unable to undergo autologous blood processing and previously ineffectively treated with expensive advanced medications for 8-275 weeks.PGs were prepared by platelet activation with human thrombin or commercial batroxobin. Median and range growth factor contents (ng/mL) were: platelet derived growth factor (PDGF-AB/-BB) 112 (31-157) and 20 (3.8-34); transforming growth factor (TGF-β1/-β2) 214 (48-289) and 0.087 (0.03-0.28); basic-fibroblast growth factor (b-FGF) 0.03 (0.006-0.214); vascular endothelial growth factor (VEGF) 1.15 (0.18-2.46); epidermal growth factor (EGF) 4.50 (0.87-6.64); insulin-like growth factor (IGF-l) 116 (72-156).In the clinical study, 222 PGs were used within 2 h of activation to treat 14 chronic skin ulcers in the 11 patients. No improvement was seen in 3 patients with 24, 27 and 30 cm3 ulcers who could be treated for no more than 4, 7 and 8 weeks due to progressively worsening clinical conditions, while 11 ulcers with 3.2 cm3 median size (range 0.2-3.6) in the remaining 8 patients showed 91 ± 14 {\%} reduction after a median of 12 weeks (range 1-20). Cost of PG treatment (19,976 euro) amounted to about 10{\%} of the ineffective advanced medication hospital reimbursement fees (191,236 euro).This study supports efficacy and feasibility of allogeneic PG to treat recalcitrant ulcers in very elderly hypomobile patients for whom autologous blood processing may be difficult.",
keywords = "Allogeneic platelet gel, Buffy coat, Platelet concentrate, Platelet growth factors, Skin ulcers",
author = "N. Greppi and L. Mazzucco and G. Galetti and F. Bona and E. Petrillo and C. Smacchia and E. Raspollini and P. Cossovich and R. Caprioli and P. Borzini and P. Rebulla and M. Marconi",
year = "2011",
month = "3",
doi = "10.1016/j.biologicals.2011.01.002",
language = "English",
volume = "39",
pages = "73--80",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients

AU - Greppi, N.

AU - Mazzucco, L.

AU - Galetti, G.

AU - Bona, F.

AU - Petrillo, E.

AU - Smacchia, C.

AU - Raspollini, E.

AU - Cossovich, P.

AU - Caprioli, R.

AU - Borzini, P.

AU - Rebulla, P.

AU - Marconi, M.

PY - 2011/3

Y1 - 2011/3

N2 - We evaluated growth factor contents and clinical efficacy of allogeneic platelet gel (PG) prepared with standard blood banking procedures from routine platelet concentrates (PCs) obtained from buffy coats. The PGs were used to treat 11 hypomobile very elderly patients unable to undergo autologous blood processing and previously ineffectively treated with expensive advanced medications for 8-275 weeks.PGs were prepared by platelet activation with human thrombin or commercial batroxobin. Median and range growth factor contents (ng/mL) were: platelet derived growth factor (PDGF-AB/-BB) 112 (31-157) and 20 (3.8-34); transforming growth factor (TGF-β1/-β2) 214 (48-289) and 0.087 (0.03-0.28); basic-fibroblast growth factor (b-FGF) 0.03 (0.006-0.214); vascular endothelial growth factor (VEGF) 1.15 (0.18-2.46); epidermal growth factor (EGF) 4.50 (0.87-6.64); insulin-like growth factor (IGF-l) 116 (72-156).In the clinical study, 222 PGs were used within 2 h of activation to treat 14 chronic skin ulcers in the 11 patients. No improvement was seen in 3 patients with 24, 27 and 30 cm3 ulcers who could be treated for no more than 4, 7 and 8 weeks due to progressively worsening clinical conditions, while 11 ulcers with 3.2 cm3 median size (range 0.2-3.6) in the remaining 8 patients showed 91 ± 14 % reduction after a median of 12 weeks (range 1-20). Cost of PG treatment (19,976 euro) amounted to about 10% of the ineffective advanced medication hospital reimbursement fees (191,236 euro).This study supports efficacy and feasibility of allogeneic PG to treat recalcitrant ulcers in very elderly hypomobile patients for whom autologous blood processing may be difficult.

AB - We evaluated growth factor contents and clinical efficacy of allogeneic platelet gel (PG) prepared with standard blood banking procedures from routine platelet concentrates (PCs) obtained from buffy coats. The PGs were used to treat 11 hypomobile very elderly patients unable to undergo autologous blood processing and previously ineffectively treated with expensive advanced medications for 8-275 weeks.PGs were prepared by platelet activation with human thrombin or commercial batroxobin. Median and range growth factor contents (ng/mL) were: platelet derived growth factor (PDGF-AB/-BB) 112 (31-157) and 20 (3.8-34); transforming growth factor (TGF-β1/-β2) 214 (48-289) and 0.087 (0.03-0.28); basic-fibroblast growth factor (b-FGF) 0.03 (0.006-0.214); vascular endothelial growth factor (VEGF) 1.15 (0.18-2.46); epidermal growth factor (EGF) 4.50 (0.87-6.64); insulin-like growth factor (IGF-l) 116 (72-156).In the clinical study, 222 PGs were used within 2 h of activation to treat 14 chronic skin ulcers in the 11 patients. No improvement was seen in 3 patients with 24, 27 and 30 cm3 ulcers who could be treated for no more than 4, 7 and 8 weeks due to progressively worsening clinical conditions, while 11 ulcers with 3.2 cm3 median size (range 0.2-3.6) in the remaining 8 patients showed 91 ± 14 % reduction after a median of 12 weeks (range 1-20). Cost of PG treatment (19,976 euro) amounted to about 10% of the ineffective advanced medication hospital reimbursement fees (191,236 euro).This study supports efficacy and feasibility of allogeneic PG to treat recalcitrant ulcers in very elderly hypomobile patients for whom autologous blood processing may be difficult.

KW - Allogeneic platelet gel

KW - Buffy coat

KW - Platelet concentrate

KW - Platelet growth factors

KW - Skin ulcers

UR - http://www.scopus.com/inward/record.url?scp=79952535521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952535521&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2011.01.002

DO - 10.1016/j.biologicals.2011.01.002

M3 - Article

C2 - 21353597

AN - SCOPUS:79952535521

VL - 39

SP - 73

EP - 80

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 2

ER -